Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction

射血分数 心力衰竭 地高辛 医学 内科学 心脏病学 安慰剂 缬沙坦 射血分数保留的心力衰竭 血压 病理 替代医学
作者
Stefanos Zafeiropoulos,Ioannis T. Farmakis,Ioannis Milioglou,Ioannis Doundoulakis,Eiran Z. Gorodeski,Stavros Konstantinides,Lauren Cooper,Stavros Zanos,Stavros Stavrakis,Grigorios Giamouzis,Javed Butler,George Giannakoulas
出处
期刊:Jacc-Heart Failure [Elsevier]
卷期号:12 (4): 616-627 被引量:5
标识
DOI:10.1016/j.jchf.2023.07.014
摘要

Medical treatment for heart failure with preserved ejection (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF) has weaker evidence compared with reduced ejection fraction, despite recent trials with an angiotensin receptor neprilysin inhibitor (ARNI) and sodium glucose co-transporter 2 inhibitors (SGLT2is). The authors aimed to estimate the aggregate therapeutic benefit of drugs for HFmrEF and HFpEF. The authors performed a systematic review of MEDLINE, CENTRAL, and Web of Science for randomized trials including patients with heart failure (HF) and left ventricular ejection fraction (LVEF) >40%, treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (analyzed together as renin-angiotensin system inhibitors [RASi]), beta-blockers (BBs), mineralocorticoid receptor antagonists (MRAs), digoxin, ARNI, and SGLT2i. An additive component network meta-analysis was performed. The primary outcome was a composite of cardiovascular (CV) death and first hospitalization for heart failure (HHF); secondary outcomes were CV death, total HHF, and all-cause mortality. The authors identified 13 studies with a total of 29,875 patients and a mean LVEF of 56.3% ± 8.7%. ARNI, MRA, and SGLT2i separately, but not RASi, BB, or digoxin, reduced the primary composite outcome compared with placebo. The combination of ARNI, BB, MRA, and SGLT2i was the most effective (HR: 0.47 [95% CI: 0.31-0.70]); this was largely explained by the triple combination of ARNI, MRA, and SGLT2i (HR: 0.56 [95% CI 0.43-0.71]). Results were similar for CV death (HR: 0.63 [95% CI 0.43-0.91] for ARNI, MRA, and SGLT2i) or total HHF (HR: 0.49 [95% CI 0.33-0.71] for ARNI, MRA, and SGLT2i) alone. In a subgroup analysis, only SGLT2i had a consistent benefit among all LVEF subgroups, whereas the triple combination had the greatest benefit in HFmrEF, robust benefit in patients with LVEF 50% to 59%, and a statistically marginal benefit in patients with LVEF ≥60%. In patients with HF and LVEF>40%, the quadruple combination of ARNI, BB, MRA, and SGLT2i provides the largest reduction in the risk of CV death and HHF; driven by the robust effect of the triple combination of ARNI, MRA, and SGLT2i. The benefit was more pronounced in HFmrEF patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
所所应助夏至采纳,获得10
刚刚
钰灵QAQ发布了新的文献求助10
1秒前
1秒前
1秒前
深情安青应助stop here采纳,获得10
4秒前
上官若男应助ZQN采纳,获得30
4秒前
4秒前
成梦完成签到,获得积分10
4秒前
5秒前
6秒前
小小菜刀完成签到,获得积分10
7秒前
8秒前
丘比特应助yang采纳,获得10
9秒前
时尚语梦完成签到 ,获得积分10
9秒前
黄浦江发布了新的文献求助10
9秒前
Loooong应助TQY采纳,获得20
10秒前
10秒前
He完成签到,获得积分10
11秒前
12秒前
12秒前
乔一乔完成签到 ,获得积分10
13秒前
无花果应助好好的i采纳,获得10
13秒前
gadfsjkdahf完成签到,获得积分10
14秒前
a初心不变发布了新的文献求助10
14秒前
激动的寒珊关注了科研通微信公众号
14秒前
14秒前
14秒前
Wang发布了新的文献求助10
15秒前
钰灵QAQ完成签到,获得积分10
15秒前
黄浦江完成签到,获得积分10
15秒前
悠悠完成签到,获得积分10
16秒前
柳听白发布了新的文献求助10
16秒前
月流瓦完成签到,获得积分10
17秒前
17秒前
17秒前
雨辰发布了新的文献求助10
18秒前
彩色夜阑完成签到,获得积分10
18秒前
gadfsjkdahf发布了新的文献求助10
19秒前
19秒前
20秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3135677
求助须知:如何正确求助?哪些是违规求助? 2786507
关于积分的说明 7777976
捐赠科研通 2442633
什么是DOI,文献DOI怎么找? 1298612
科研通“疑难数据库(出版商)”最低求助积分说明 625205
版权声明 600847